News Articles | Pfizer Singapore

Biopharma Leaders Unite To Stand With Science

Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine

Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

RECENT PRESS RELEASES

18/03/2020 - Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older

18/03/2020 - Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

18/03/2020 - Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns

17/03/2020 - Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

13/03/2020 - EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study

13/03/2020 - Pfizer Outlines Five-Point Plan to Battle COVID-19

04/03/2020 - Susan Hockfield Elected to Pfizer’s Board of Directors

02/03/2020 - U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis

27/02/2020 - James Quincey Elected to Pfizer’s Board of Directors

27/02/2020 - Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

27/02/2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

25/02/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

18/02/2020 - European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

11/02/2020 - XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC

31/01/2020 - Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)